Correlates of immune protection against human rotaviruses: natural infection and vaccination
- PMID: 38459213
- DOI: 10.1007/s00705-024-05975-y
Correlates of immune protection against human rotaviruses: natural infection and vaccination
Abstract
Species A rotaviruses are the leading viral cause of acute gastroenteritis in children under 5 years of age worldwide. Despite progress in the characterization of the pathogenesis and immunology of rotavirus-induced gastroenteritis, correlates of protection (CoPs) in the course of either natural infection or vaccine-induced immunity are not fully understood. There are numerous factors such as serological responses (IgA and IgG), the presence of maternal antibodies (Abs) in breast milk, changes in the intestinal microbiome, and rotavirus structural and non-structural proteins that contribute to the outcome of the CoP. Indeed, while an intestinal IgA response and its surrogate, the serum IgA level, are suggested as the principal CoPs for oral rotavirus vaccines, the IgG level is more likely to be a CoP for parenteral non-replicating rotavirus vaccines. Integrating clinical and immunological data will be instrumental in improving rotavirus vaccine efficacy, especially in low- and middle-income countries, where vaccine efficacy is significantly lower than in high-income countries. Further knowledge on CoPs against rotavirus disease will be helpful for next-generation vaccine development. Herein, available data and literature on interacting components and proposed CoPs against human rotavirus disease are reviewed, and limitations and gaps in our knowledge in this area are discussed.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Similar articles
-
Plasma VP8∗-Binding Antibodies in Rotavirus Infection and Oral Vaccination in Young Bangladeshi Children.J Pediatric Infect Dis Soc. 2022 Apr 30;11(4):127-133. doi: 10.1093/jpids/piab120. J Pediatric Infect Dis Soc. 2022. PMID: 34904667 Free PMC article.
-
Postvaccination Serum Antirotavirus Immunoglobulin A as a Correlate of Protection Against Rotavirus Gastroenteritis Across Settings.J Infect Dis. 2020 Jun 29;222(2):309-318. doi: 10.1093/infdis/jiaa068. J Infect Dis. 2020. PMID: 32060525 Free PMC article.
-
Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group.Vaccine. 1995 Sep;13(13):1226-32. doi: 10.1016/0264-410x(95)00060-e. Vaccine. 1995. PMID: 8578808 Clinical Trial.
-
Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies.BMC Infect Dis. 2017 Aug 15;17(1):569. doi: 10.1186/s12879-017-2613-4. BMC Infect Dis. 2017. PMID: 28810833 Free PMC article.
-
Rotavirus vaccines and vaccination in Latin America.Rev Panam Salud Publica. 2000 Nov;8(5):305-31. doi: 10.1590/s1020-49892000001000002. Rev Panam Salud Publica. 2000. PMID: 11190969 Review.
Cited by
-
Rotavirus Infections: Pathophysiology, Symptoms, and Vaccination.Pathogens. 2025 May 14;14(5):480. doi: 10.3390/pathogens14050480. Pathogens. 2025. PMID: 40430800 Free PMC article. Review.
-
Strain- and vaccine-specific effects of serum antibodies in the protection of intestinal SARS-CoV-2 infection.medRxiv [Preprint]. 2025 Mar 28:2025.03.24.25324570. doi: 10.1101/2025.03.24.25324570. medRxiv. 2025. PMID: 40196264 Free PMC article. Preprint.
-
Evaluating Nanoparticulate Vaccine Formulations for Effective Antigen Presentation and T-Cell Proliferation Using an In Vitro Overlay Assay.Vaccines (Basel). 2024 Sep 13;12(9):1049. doi: 10.3390/vaccines12091049. Vaccines (Basel). 2024. PMID: 39340079 Free PMC article.
-
High Detection Rate of Rotavirus Infection Among Children Admitted with Acute Gastroenteritis to Six Public Hospitals in Luanda Province After the Introduction of Rotarix® Vaccine: A Cross-Sectional Study.Viruses. 2024 Dec 20;16(12):1949. doi: 10.3390/v16121949. Viruses. 2024. PMID: 39772256 Free PMC article.
References
-
- International Vaccine Access Center. http://view-hub.org . Accessed 03 Jan 2023.
-
- Afchangi A, Arashkia A, Shahosseini Z, Jalilvand S, Marashi SM, Roohvand F, Mohajel N, Shoja Z (2018) Immunization of mice by rotavirus NSP4-VP6 fusion protein elicited stronger responses compared to VP6 alone. Viral Immunol 31:233–241 - PubMed
-
- Afchangi A, Latifi T, Jalilvand S, Marashi SM, Shoja Z (2021) Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins. Adv Virol 166:995–1006
-
- Afchangi A, Jalilvand S, Arashkia A, Latifi T, Farahmand M, Shirazi MMA, Nasab SDM, Marashi SM, Roohvand F, Shoja Z (2022) Co-administration of rotavirus nanospheres VP6 and NSP4 proteins enhanced the anti-NSP4 humoral responses in immunized mice. Microb Pathog 163:105405 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous